-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
SOLUTIONS
-
Research & Development
-
Real World Evidence
-
Commercialization
-
Safety & Regulatory Compliance
-
Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
- Information Partner Services
- Financial Institutions
- Global Public Health
- Government
- Patient Associations
- Payers
- Providers
THERAPEUTIC AREAS
- Cardiovascular
- Cell and Gene Therapy
- Central Nervous System
- GI & Hepatology
- Infectious Diseases and Vaccines
- Oncology
- Pediatrics
- Rare Diseases
- View All
Impacting People's Lives
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewResearch & Development Quick Links
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWReal World Evidence Quick Links
See markets more clearly. Opportunities more often.
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWCommercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWSafety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWTechnology Quick Links
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
BLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSTHE IQVIA INSTITUTE
An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTS
FEATURED INNOVATIONS
-
IQVIA Connected Intelligence™
-
IQVIA Healthcare-grade AI™
-
IQVIA AI Assistant
-
Human Data Science Cloud
-
IQVIA Innovation Hub
-
Decentralized Trials
-
Patient Experience Solutions with Apple devices
WHO WE ARE
- Our Story
- Our Impact
- Commitment to Public Health
- Code of Conduct
- Sustainability
- Privacy
- Executive Team
NEWS & RESOURCES
Unlock your potential to drive healthcare forward
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
IQVIA AI is Healthcare-grade AI
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
Meet the IQVIA AI Assistant
Your new expert analyst is here. Be at the forefront of data-driven decision-making with a new generative AI tool that enables you to interact with our products and solutions like never before. Get results you can trust, faster.
LEARN MORE
Your healthcare data deserves more than just a cloud.
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
Proven, faster DCT solutions
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
IQVIA Patient Experience Solutions with Apple devices
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREWORKING AT IQVIA
Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORELIFE AT IQVIA
Careers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE
WE’RE HIRING
"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSInstitute Report
Diabetes Costs and Affordability in the United States
Jun 29, 2020
ABOUT THE REPORT
Even in the current healthcare climate, which is feeling the impact of the social and economic disruptions related to COVID-19, healthcare and medicine costs remain a key concern for patients, payers, and policymakers. Diabetes is a high-profile therapy area that is often considered a driver of financial challenges for both payers and patients. It has a large and growing patient population, ranks among the top three therapy classes in terms of both utilization and drug spend for both commercial payers and Medicare, and contributes significantly to CMS costs due to high volumes dispensed. However, several key misunderstandings persist around the prices of these critical medicines. As policymakers consider significant changes to U.S. drug pricing, including rules potentially impacting diabetes pricing, this report provides analyses of pricing, and context to inform those decisions.
REPORT SUMMARY
Diabetes costs have been a significant focus for stakeholders. The report provides detailed analyses around diabetes drug pricing, including list price, net manufacturer price, and out-of-pocket costs for patients as a function of various insurance programs. Diabetes prices have risen significantly in the past five years on a list-price basis though manufacturer net revenues have been declining and for patient out-of-pocket costs, reductions have not been uniformly observed though they have been flat or have risen only slightly overall. The report also looks at prescription abandonment related to out-of-pocket costs, and how these costs can interrupt a patient’s ability to pay. The report examines the impact of insurance coverage and finds that commercially-insured patients have higher initial cost exposure than Medicare patients, but can use coupons to offset costs and a significant proportion are doing so, such that their final out-of-pocket costs are similar to that of Medicare patients. Finally, the report details current U.S. policies and other shifts in the diabetes landscape that will impact diabetes spending over the next few years.
Key Findings
PRICING
Invoice prices for diabetes medicines have been growing above inflation while net prices have been declining-to-flat for five years
- The use of price-protection contracts and the presence of statutory rebates in Medicaid are among the most impactful drivers of lower net prices.
- As net prices have declined, patient out-of-pocket costs have been flat to rising slightly.
PATIENT OUT-OF-POCKET COST
Initial copays for diabetes medicines are higher for commercial patients than Medicare patients, though their final out-of-pocket costs are similar
- For most commercially-insured patients, fixed copays still apply in traditional insurance plans, while a rising proportion have high-deductible health plans (HDHP).
- Newer generation drugs have been less preferred within certain commercial plans than historically, leading to higher copays, though much of this higher cost exposure has been offset through coupons.
ABANDONMENT
Diabetes patients facing higher costs have higher abandonment rates for prescriptions, however, the percentage of claims greater than $91 dollars is below 10% of total claims
- Abandonment is a term reflecting the preparation of a prescription for an individual patient which is not taken home, and for diabetes patients, abandonment is highest when costs are above $91.
- The majority of diabetes prescriptions are low-cost — with less than $30 patient out-of-pocket cost — and only 4% of patients abandon those prescriptions at the pharmacy.
POLICY IMPACT
Recent policies and environmental factors, such as updated tax rules and availability of novel biosimilars, have the potential to lower patient costs for diabetes
- The IRS extended the group of therapies that are considered preventive in high-deductible plans with health savings accounts (HDHP/HSA). Diabetics could benefit from savings for several of their drugs or medical supplies including hypertension, heart disease, cholesterol among others.
- The new CMS Senior Savings Model for diabetes would enable some plans to offer lower patient costs for diabetes and as with all Part D plan choices.
- Non-original versions of insulin glargine and lispro, while not approved through the biosimilar pathway, continue to contribute to lower costs for some patients and will likely see wider uptake.